Drug intelligence / Profile preview

Huoxia Cold Granules

Development stage: Unknown
Lead developer: Yiling Pharmaceutical
Administration: Oral

Overview

Huoxia Cold Granules is a Traditional Chinese Medicine (TCM) formulation developed by Shijiazhuang Yiling Pharmaceutical for the treatment of the common cold. It is specifically indicated for patients presenting with the TCM pattern of 'wind attack on the exterior with dampness obstructing the middle' (风感外袭，湿阻中焦). The drug is designed to alleviate symptoms such as fever, headache, nasal congestion, and gastrointestinal discomfort by dispelling external wind pathogens and resolving internal dampness. As of 2025, Huoxia Cold Granules is being evaluated in Phase III clinical trials in China to establish its efficacy and safety profile in adults with the common cold.

Brand names: Huoxia Cold Granules
Other names: 藿夏感冒颗粒Huoxia Ganmao Keli

Beyond the preview

Go deeper on Huoxia Cold Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huoxia Cold Granules.

Explore the full profile